These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12482393)

  • 1. Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus.
    Sami N; Bhol KC; Ahmed AR
    Clin Immunol; 2002 Nov; 105(2):192-8. PubMed ID: 12482393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris.
    Sami N; Bhol KC; Ahmed RA
    Eur J Dermatol; 2003; 13(4):377-81. PubMed ID: 12948919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up and treatment responses.
    Sami N; Bhol KC; Ahmed AR
    Clin Exp Immunol; 2001 Sep; 125(3):492-8. PubMed ID: 11531959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catabolism of pemphigus foliaceus autoantibodies by high-dose IVIg therapy.
    Aoyama Y; Moriya C; Kamiya K; Nagai M; Rubenstein D; Iwatsuki K; Kitajima Y
    Eur J Dermatol; 2011; 21(1):58-61. PubMed ID: 21233063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic features of pemphigus vulgaris in patients with bullous pemphigoid. Molecular analysis of autoantibody profile.
    Sami N; Bhol KC; Beutner EH; Plunkett RW; Leiferman KM; Ahmed AR
    Dermatology; 2002; 204(2):108-17. PubMed ID: 11937735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four mild but refractory cases of pemphigus foliaceus successfully treated with intravenous immunoglobulin.
    Kawakami T; Koga H; Saruta H; Ueda A; Inoue Y; Soma Y; Ishii N; Hashimoto T
    J Dermatol; 2013 Nov; 40(11):869-73. PubMed ID: 24127870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile.
    Amagai M; Tsunoda K; Zillikens D; Nagai T; Nishikawa T
    J Am Acad Dermatol; 1999 Feb; 40(2 Pt 1):167-70. PubMed ID: 10025740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An experience for ELISA for desmoglein 1, suggesting a possible diagnostic help to determine the initial therapy for pemphigus foliaceus.
    Aoyama Y; Tsujimura Y; Funabashi M; Sato M; Kamiya H; Kitajima Y
    Eur J Dermatol; 2000; 10(1):18-21. PubMed ID: 10694292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intravenous immunoglobulin therapy: ELISA measurement of antidesmogleins 1 and 3 in three patients with pemphigus vulgaris].
    Suárez-Fernández R; Longo I; Avilés JA; Bueno C; Rodríguez-Mahou M; Lázaro P
    Rev Clin Esp; 2006 Nov; 206(10):499-503. PubMed ID: 17129517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The plant lectin wheat germ agglutinin inhibits the binding of pemphigus foliaceus autoantibodies to desmoglein 1 in a majority of patients and prevents pathomechanisms of pemphigus foliaceus in vitro and in vivo.
    Ortiz-Urda S; Elbe-Bürger A; Smolle J; Marquart Y; Chudnovsky Y; Ridky TW; Bernstein P; Wolff K; Rappersberger K
    J Immunol; 2003 Dec; 171(11):6244-50. PubMed ID: 14634141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus.
    Czernik A; Beutner EH; Bystryn JC
    J Am Acad Dermatol; 2008 May; 58(5):796-801. PubMed ID: 18423257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins.
    Herzog S; Schmidt E; Goebeler M; Bröcker EB; Zillikens D
    Acta Derm Venereol; 2004; 84(1):48-52. PubMed ID: 15040478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Desmoglein 1 and 3 Autoantibody Levels in Endemic Pemphigus Foliaceus and Pemphigus Vulgaris from Brazil.
    Oliveira LA; Marquart-Filho A; Trevilato G; Timoteo RP; Mukai M; Roselino AM; Petzl-Erler ML
    Clin Lab; 2016 Jul; 62(7):1209-1216. PubMed ID: 28164651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical transition between pemphigus foliaceus and pemphigus vulgaris correlates well with the changes in autoantibody profile assessed by an enzyme-linked immunosorbent assay.
    Komai A; Amagai M; Ishii K; Nishikawa T; Chorzelski T; Matsuo I; Hashimoto T
    Br J Dermatol; 2001 Jun; 144(6):1177-82. PubMed ID: 11422038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The transition of pemphigus vulgaris into pemphigus foliaceus: a reflection of changing desmoglein 1 and 3 autoantibody levels in pemphigus vulgaris.
    Harman KE; Gratian MJ; Shirlaw PJ; Bhogal BS; Challacombe SJ; Black MM
    Br J Dermatol; 2002 Apr; 146(4):684-7. PubMed ID: 11966706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of anti-desmoglein-1 and anti-desmoglein-3 autoantibody titers in pemphigus patients at the time of the initial diagnosis and after clinical remission.
    Russo I; De Siena FP; Saponeri A; Alaibac M
    Medicine (Baltimore); 2017 Nov; 96(46):e8801. PubMed ID: 29145342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid.
    Sami N; Ali S; Bhol KC; Ahmed AR
    J Eur Acad Dermatol Venereol; 2003 Nov; 17(6):641-5. PubMed ID: 14761129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-desmoglein 1 antibodies in Tunisian healthy subjects: arguments for the role of environmental factors in the occurrence of Tunisian pemphigus foliaceus.
    Kallel Sellami M; Ben Ayed M; Mouquet H; Drouot L; Zitouni M; Mokni M; Cerruti M; Turki H; Fezza B; Mokhtar I; Ben Osman A; Zahaf A; Kamoun MR; Joly P; Masmoudi H; Makni S; Tron F; Gilbert D
    Clin Exp Immunol; 2004 Jul; 137(1):195-200. PubMed ID: 15196262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of pemphigus antigens in drug-induced pemphigus vulgaris and pemphigus foliaceus.
    Brenner S; Bialy-Golan A; Anhalt GJ
    J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):919-23. PubMed ID: 9204055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels.
    Harman KE; Seed PT; Gratian MJ; Bhogal BS; Challacombe SJ; Black MM
    Br J Dermatol; 2001 Apr; 144(4):775-80. PubMed ID: 11298536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.